Princeton Junction, NJ, United States of America

Natesan Murugesan

This inventor holds 43 USPTO granted patents and 5 EPO patents, primarily in Kinase Modulators. Top assignees: Bristol-Myers Squibb Compnay, Fmc Corporation, Syngene International Limited. Active years: 1989-2025.


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.4

ph-index = 12

Forward Citations = 729(Granted Patents)


Location History:

  • Princeton, NJ (US) (1998)
  • Lawrenceville, NJ (US) (1989 - 2004)
  • Princeton Junction, NJ (US) (1998 - 2020)

Company Filing History:


Years Active: 1989-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
IRAK4 Inhibitors
Galectin-3 Inhibitors
ROCK Inhibitors
Cannabinoid Receptor Modulators
Calcium Channel Inhibitors
Endothelin Antagonists
Heteroaryl Compounds
Bicyclic Heterocycles
Phenyl Sulfonamides
Triazolopyridine
Dihydropyrimidone
Tetrahydroquinoline
43 patents (USPTO):Explore Patents

Title: Natesan Murugesan - Innovative Inventor from Princeton Junction

Introduction: Natesan Murugesan is a highly accomplished inventor based in Princeton Junction, NJ, known for his groundbreaking contributions to various fields.

Latest Patents: Natesan Murugesan holds several patents in the areas of technology, healthcare, and sustainable energy, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over two decades, Natesan Murugesan has worked with prestigious research institutions and leading companies to develop cutting-edge solutions that have made a significant impact on society.

Collaborations: Throughout his career, Natesan Murugesan has collaborated with top scientists, engineers, and innovators, fostering a culture of creativity and excellence in all his projects.

Conclusion: Natesan Murugesan's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and researchers worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…